Explore Your Local Site

Looks like you've landed on our   site. Let's take you home:    

Please note that the content and products on the    site might not be available in your region.

 

Choose the language:

  Homepage
Continue on the current website:  

 

Bayer Logo
Region
Book a demo

Prostate Service Line*​

Explore AI apps for multiple Prostate pathologies/conditions on the Calantic platform.

Prostate icon

Prostatic lesions detection and characterization

Quantib logo

Quantib Prostate* is an image post-processing software that provides the user with processing, visualization, and editing of prostate MRI images. The software facilitates the analysis and study review of MR data sets and provides additional mathematical and/or statistical analysis. The resulting analysis can be displayed in a variety of formats, including images overlaid onto source MRI images.

Quantib Prostate functionality includes registered multiparametric-MRI viewing, with the option to view images combined into a single image to support visualization. The software can be used for semiautomatic segmentation of anatomical structures and provides volume computations, together with tools for manual editing. PI-RADS scoring is possible using a structured workflow1.

MRI​​

Learn more

Extra & Prostatic lesions Detection and characterization

Exini

aPromise* is intended to be used with PSMA - PET/CT imaging. The software provides a clinical application for oncology including detection and quantification of lesion candidates in Bone, Lymph Node and Prostate2.

PET/CT​​​​

Learn more

Bone metastasis Detection and characterization

Exini

aBSI* provides detection and quantification of lesions for evaluation of Prostate Cancer Progression. EXINI’s aBSI mark the lesions and to quantify the disease burden - Automated Bone Scan Index (aBSI)3.

Bone scintigraphy​​​​

Learn more
    Legal Mentions

    *Currently not available within the Calantic Viewer. Separately distributed by Bayer.​​

    • Quantib Prostate has CE marking (CE0344) and risk class IIb. Quantib Prostate manufactured for DeepHealth by Quantib B.V.​​
    • aPROMISE has CE marking (CE0123) and risk class IIa.​​
    • aBSI has CE marking (CE0123) and risk class IIa.​​
      References
      1. Instructions for Use Quantib Prostate, software version 2.1
      2. Instructions for Use aPROMISE, software version 1.4
      3. Instructions for Use aBSI, software version 3.6
      Request a demo wave top

      Request a demo and discover how to

      • Centralize your AI apps on one platform
      • Deploy service lines tailored to specific body regions/pathologies
      • Integrate Calantic into your existing health information technology system
      Get a Demo
      Request a demo

      Prostate Service Line*​

      Prostate service line

      PATHOLOGY​

      Prostatic lesions​

      VENDOR

      Quantib

      APP Quantib Prostate​

      DESCRIPTION​

      Quantib Prostate provides the user with processing, visualization, and editing of prostate MRI images. The software can be used for semi-automatic segmentation of anatomical structures and provides volume computations, together with tools for manual editing. PI-RADS scoring is possible using a structured workflow.1

      MODALITY​
      MRI


      Quantib Prostate has CE marking (CE0344) and risk class IIb.​​

      PATHOLOGY​

      Prostatic/Extraprostatic lesions​

      VENDOR

      EXINI

      APP aPROMISE

      DESCRIPTION​

      aPromise is intended to be used with PSMA - PET/CT imaging. The software provides a clinical application for oncology including detection and quantification of lesion candidates (in Bone, Lymph Node and Prostate).2

      MODALITY​​
      PET/CT


      aPROMISE has CE marking (CE0123) and risk class IIa.​​

      PATHOLOGY​​

      Extraprostatic lesions​​

      VENDOR​

      Exini

      APP aBSI

      DESCRIPTION​​

      aBSI provides detection and quantification of lesions for evaluation of Prostate Cancer Progression. EXINI’s aBSI mark the lesions and to quantify the disease burden - Automated Bone Scan Index (aBSI).3​

      MODALITY​​
      Bone scintigraphy​


      aBSI has CE marking (CE0123) and risk class IIa.​​

      *Currently not available within the Calantic Viewer. Separately distributed by Bayer.​​

      1. Instructions for Use Quantib Prostate, software version 2.1
      2. Instructions for Use aPROMISE, software version 1.4
      3. Instructions for Use aBSI, software version 3.6
      Bayer Logo
      Calantic Logo

      Contact Us

      Alt tag

      Solutions

      © 2024 Bayer

      The descriptions, claims and visuals for all non-Bayer owned applications originate and are obtained from the application providers, or excerpted from publicly available information. Bayer is providing this content for your information, but does not own and control such content.

      BAYER, the Bayer Cross and Calantic are trademarks owned by Bayer and/or registered in the U.S. and/or other countries. Other trademarks and company names mentioned herein are properties of their respective owners.

      This is intended to provide information for healthcare professionals and other relevant decision makers in the European Union, United Kingdom and Switzerland. Not all offerings are available in all markets. For availability specific to your country please contact your local Bayer representative. These materials are exclusively for professional use.

      Calantic is ISO 27001 certified. The product Calantic Viewer has CE marking (CE2797). Complies with medical device legislation. Consult the operating instructions of a product for its intended use, characteristics and performance, contraindications, name of the manufacturer or its authorized representative and other essential information. The operating instructions of the product Calantic Viewer can be found on https://eifu.radiology.bayer.com/medicaldevice

      You are encouraged to report adverse events; reporting information can be found on https://www.bayer.com/en/pharma/report-side-effect

      Any individuals depicted in this website are actors and not actual health care providers or patients. All patient data is fictitious. Images are an artistic representation for illustrative purposes only.

      PP-CALA-ALL-0886-1 December 2024